Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
21 participants
INTERVENTIONAL
2004-01-14
2014-08-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
In addition, specific tumor accumulation and metabolic fate of 131-I-NM404 will be determined in NSCLC tumors collected in 5 patients (part 2 - complete). Lastly, the study will collect preliminary data on imaging NSCLC tumors in up to 12 patients with evaluable disease (part 3 - ongoing).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Feasibility Study of Enhanced MRI for Early Stage Non Small Cell Lung Cancer (NSCLC)
NCT01799135
Factors Determining the Prognosis in NSCLC Stage IV
NCT04306094
Improving Pulmonary Function Following Radiation Therapy
NCT02843568
Application of 4DCT-Based Pulmonary Ventilation Imaging in Lung Cancer Radiotherapy
NCT07312682
A Study of Molecular Residual, Dynamic Monitoring and Recurrence of Stage III Driver Mutated NSCLC
NCT06443684
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Diagnostic: iodine I-124 NM404 CT/PET scan
Patients undergo iodine I-124 NM404 CT/PET scan at 1-2, 4-6, 24, and 48 hours and at 5-10 days.
I124-NM404
I-124-NM404
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
I124-NM404
I-124-NM404
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Disease is evaluable by CT scan
* At least 18 years old. Women cannot be pregnant or breastfeeding
* Karnofsky score \>/= to 60
* Adequate renal/hepatic function
* Adequate blood cell count levels
Exclusion Criteria
* Other active cancers
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Cellectar Biosciences, Inc.
INDUSTRY
University of Wisconsin, Madison
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Anne M Traynor, MD
Role: PRINCIPAL_INVESTIGATOR
University of Wisconsin, Madison
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Wisconsin Carbone Comprehensive Cancer Center
Madison, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
124I-CLR1404
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
CO02505
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.